#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Designed scaffolds should be biocompatible and biodegradable , capable of producing an extracellular matrix ( ECM ) by supporting the cell ’s adhesion and proliferation .
2-1	16-24	Designed	object[2]	new[2]	coref	5-8[0_2]
2-2	25-34	scaffolds	object[2]	new[2]	_	_
2-3	35-41	should	_	_	_	_
2-4	42-44	be	_	_	_	_
2-5	45-58	biocompatible	_	_	_	_
2-6	59-62	and	_	_	_	_
2-7	63-76	biodegradable	_	_	_	_
2-8	77-78	,	_	_	_	_
2-9	79-86	capable	_	_	_	_
2-10	87-89	of	_	_	_	_
2-11	90-99	producing	_	_	_	_
2-12	100-102	an	object[3]	new[3]	appos	2-16[0_3]
2-13	103-116	extracellular	object[3]	new[3]	_	_
2-14	117-123	matrix	object[3]	new[3]	_	_
2-15	124-125	(	_	_	_	_
2-16	126-129	ECM	object	giv	_	_
2-17	130-131	)	_	_	_	_
2-18	132-134	by	_	_	_	_
2-19	135-145	supporting	_	_	_	_
2-20	146-149	the	abstract[6]|abstract[7]	new[6]|new[7]	ana|coref|ana|coref	3-1[0_7]|6-13[45_6]|3-1[0_7]|6-13[45_6]
2-21	150-154	cell	place[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	coref	4-45[0_5]
2-22	155-157	’s	place[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
2-23	158-166	adhesion	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-24	167-170	and	abstract[7]	new[7]	_	_
2-25	171-184	proliferation	abstract[7]|event	new[7]|new	coref	4-45[31_0]
2-26	185-186	.	_	_	_	_

#Text=They should also have porosity to promote nutrient transportation , and their mechanical properties should be similar to native tissue .
3-1	187-191	They	abstract	giv	ana	3-12
3-2	192-198	should	_	_	_	_
3-3	199-203	also	_	_	_	_
3-4	204-208	have	_	_	_	_
3-5	209-217	porosity	substance	new	_	_
3-6	218-220	to	_	_	_	_
3-7	221-228	promote	_	_	_	_
3-8	229-237	nutrient	substance|abstract[12]	new|new[12]	coref|coref	4-33|4-33
3-9	238-252	transportation	abstract[12]	new[12]	_	_
3-10	253-254	,	_	_	_	_
3-11	255-258	and	_	_	_	_
3-12	259-264	their	abstract|abstract[14]	giv|new[14]	coref|coref|coref|coref	12-3[86_14]|30-34[241_0]|12-3[86_14]|30-34[241_0]
3-13	265-275	mechanical	abstract[14]	new[14]	_	_
3-14	276-286	properties	abstract[14]	new[14]	_	_
3-15	287-293	should	_	_	_	_
3-16	294-296	be	_	_	_	_
3-17	297-304	similar	_	_	_	_
3-18	305-307	to	_	_	_	_
3-19	308-314	native	object[15]	new[15]	coref	12-7[0_15]
3-20	315-321	tissue	object[15]	new[15]	_	_
3-21	322-323	.	_	_	_	_

#Text=To meet these requirements , a high surface area and an interconnected three-dimensional ( 3D ) porous structure with sizes ranging between 200 and 600 μm are essential , while also providing nutrient transfer , waste disposal , cellular infiltration , neovascularization , and cell proliferation .
4-1	324-326	To	_	_	_	_
4-2	327-331	meet	_	_	_	_
4-3	332-337	these	abstract[16]	new[16]	_	_
4-4	338-350	requirements	abstract[16]	new[16]	_	_
4-5	351-352	,	_	_	_	_
4-6	353-354	a	quantity[18]	new[18]	_	_
4-7	355-359	high	quantity[18]	new[18]	_	_
4-8	360-367	surface	place|quantity[18]	new|new[18]	_	_
4-9	368-372	area	quantity[18]	new[18]	_	_
4-10	373-376	and	_	_	_	_
4-11	377-379	an	abstract[20]	new[20]	_	_
4-12	380-394	interconnected	abstract[20]	new[20]	_	_
4-13	395-412	three-dimensional	abstract[20]	new[20]	_	_
4-14	413-414	(	abstract[20]	new[20]	_	_
4-15	415-417	3D	abstract|abstract[20]	new|new[20]	_	_
4-16	418-419	)	abstract[20]	new[20]	_	_
4-17	420-426	porous	abstract[20]	new[20]	_	_
4-18	427-436	structure	abstract[20]	new[20]	_	_
4-19	437-441	with	abstract[20]	new[20]	_	_
4-20	442-447	sizes	abstract[20]|quantity	new[20]|new	_	_
4-21	448-455	ranging	_	_	_	_
4-22	456-463	between	_	_	_	_
4-23	464-467	200	quantity	new	_	_
4-24	468-471	and	_	_	_	_
4-25	472-475	600	quantity	new	_	_
4-26	476-478	μm	person	new	_	_
4-27	479-482	are	_	_	_	_
4-28	483-492	essential	_	_	_	_
4-29	493-494	,	_	_	_	_
4-30	495-500	while	_	_	_	_
4-31	501-505	also	_	_	_	_
4-32	506-515	providing	_	_	_	_
4-33	516-524	nutrient	substance|abstract[26]	giv|new[26]	_	_
4-34	525-533	transfer	abstract[26]	new[26]	_	_
4-35	534-535	,	_	_	_	_
4-36	536-541	waste	abstract[27]	new[27]	_	_
4-37	542-550	disposal	abstract[27]	new[27]	_	_
4-38	551-552	,	_	_	_	_
4-39	553-561	cellular	abstract[28]	new[28]	_	_
4-40	562-574	infiltration	abstract[28]	new[28]	_	_
4-41	575-576	,	_	_	_	_
4-42	577-595	neovascularization	substance	new	_	_
4-43	596-597	,	_	_	_	_
4-44	598-601	and	_	_	_	_
4-45	602-606	cell	place|event[31]	giv|giv[31]	coref|coref|coref|coref	5-18|14-16[0_31]|5-18|14-16[0_31]
4-46	607-620	proliferation	event[31]	giv[31]	_	_
4-47	621-622	.	_	_	_	_

#Text=Natural polymers are preferred materials for producing scaffolds , due to their better overall interactions with various cell types , and their lack of toxicity .
5-1	623-630	Natural	substance[32]	new[32]	coref	6-3[42_32]
5-2	631-639	polymers	substance[32]	new[32]	_	_
5-3	640-643	are	_	_	_	_
5-4	644-653	preferred	_	_	_	_
5-5	654-663	materials	substance	new	ana	5-12
5-6	664-667	for	_	_	_	_
5-7	668-677	producing	_	_	_	_
5-8	678-687	scaffolds	object	giv	_	_
5-9	688-689	,	_	_	_	_
5-10	690-693	due	_	_	_	_
5-11	694-696	to	_	_	_	_
5-12	697-702	their	substance|abstract[36]	giv|new[36]	ana|ana	5-22|5-22
5-13	703-709	better	abstract[36]	new[36]	_	_
5-14	710-717	overall	abstract[36]	new[36]	_	_
5-15	718-730	interactions	abstract[36]	new[36]	_	_
5-16	731-735	with	abstract[36]	new[36]	_	_
5-17	736-743	various	abstract[36]|abstract[38]	new[36]|new[38]	_	_
5-18	744-748	cell	abstract[36]|place|abstract[38]	new[36]|giv|new[38]	coref	6-13
5-19	749-754	types	abstract[36]|abstract[38]	new[36]|new[38]	_	_
5-20	755-756	,	_	_	_	_
5-21	757-760	and	_	_	_	_
5-22	761-766	their	substance|abstract[40]	giv|new[40]	coref|coref	15-4[126_0]|15-4[126_0]
5-23	767-771	lack	abstract[40]	new[40]	_	_
5-24	772-774	of	abstract[40]	new[40]	_	_
5-25	775-783	toxicity	abstract[40]|abstract	new[40]|new	_	_
5-26	784-785	.	_	_	_	_

#Text=However , synthetic polymers are cheaper and allow chemical functionalization to assist cell adhesion despite the immune response .
6-1	786-793	However	_	_	_	_
6-2	794-795	,	_	_	_	_
6-3	796-805	synthetic	substance[42]	giv[42]	coref	7-1[47_42]
6-4	806-814	polymers	substance[42]	giv[42]	_	_
6-5	815-818	are	_	_	_	_
6-6	819-826	cheaper	_	_	_	_
6-7	827-830	and	_	_	_	_
6-8	831-836	allow	_	_	_	_
6-9	837-845	chemical	abstract[43]	new[43]	_	_
6-10	846-863	functionalization	abstract[43]	new[43]	_	_
6-11	864-866	to	_	_	_	_
6-12	867-873	assist	_	_	_	_
6-13	874-878	cell	place|abstract[45]	giv|giv[45]	coref|coref|coref|coref	8-12|14-12[122_45]|8-12|14-12[122_45]
6-14	879-887	adhesion	abstract[45]	giv[45]	_	_
6-15	888-895	despite	_	_	_	_
6-16	896-899	the	abstract[46]	new[46]	_	_
6-17	900-906	immune	abstract[46]	new[46]	_	_
6-18	907-915	response	abstract[46]	new[46]	_	_
6-19	916-917	.	_	_	_	_

#Text=The preferred synthetic polymers used for scaffold synthesis include poly(l-lactic acid ) ( PLLA ) , poly(glycolic acid ) ( PGA ) , poly(caprolactone ) ( PCL ) , and poly(lactic- co -glycolic ) acid ( PLGA ) .
7-1	918-921	The	substance[47]	giv[47]	coref	8-3[55_47]
7-2	922-931	preferred	substance[47]	giv[47]	_	_
7-3	932-941	synthetic	substance[47]	giv[47]	_	_
7-4	942-950	polymers	substance[47]	giv[47]	_	_
7-5	951-955	used	_	_	_	_
7-6	956-959	for	_	_	_	_
7-7	960-968	scaffold	abstract|abstract[49]	new|new[49]	_	_
7-8	969-978	synthesis	abstract[49]	new[49]	_	_
7-9	979-986	include	_	_	_	_
7-10	987-1000	poly(l-lactic	substance[50]	new[50]	_	_
7-11	1001-1005	acid	substance[50]	new[50]	_	_
7-12	1006-1007	)	_	_	_	_
7-13	1008-1009	(	_	_	_	_
7-14	1010-1014	PLLA	_	_	_	_
7-15	1015-1016	)	_	_	_	_
7-16	1017-1018	,	_	_	_	_
7-17	1019-1032	poly(glycolic	_	_	_	_
7-18	1033-1037	acid	_	_	_	_
7-19	1038-1039	)	_	_	_	_
7-20	1040-1041	(	_	_	_	_
7-21	1042-1045	PGA	_	_	_	_
7-22	1046-1047	)	_	_	_	_
7-23	1048-1049	,	_	_	_	_
7-24	1050-1067	poly(caprolactone	_	_	_	_
7-25	1068-1069	)	_	_	_	_
7-26	1070-1071	(	_	_	_	_
7-27	1072-1075	PCL	_	_	_	_
7-28	1076-1077	)	_	_	_	_
7-29	1078-1079	,	_	_	_	_
7-30	1080-1083	and	_	_	_	_
7-31	1084-1096	poly(lactic-	abstract[52]	new[52]	appos	7-37[0_52]
7-32	1097-1099	co	abstract|abstract[52]	new|new[52]	_	_
7-33	1100-1109	-glycolic	abstract[52]	new[52]	_	_
7-34	1110-1111	)	abstract[52]	new[52]	_	_
7-35	1112-1116	acid	abstract[52]	new[52]	_	_
7-36	1117-1118	(	_	_	_	_
7-37	1119-1123	PLGA	abstract	giv	_	_
7-38	1124-1125	)	_	_	_	_
7-39	1126-1127	.	_	_	_	_

#Text=Composites with natural polymers are also available with better hydrophilicity , cell attachment , and biodegradability .
8-1	1128-1138	Composites	object[54]	new[54]	coref	15-1[125_54]
8-2	1139-1143	with	object[54]	new[54]	_	_
8-3	1144-1151	natural	object[54]|substance[55]	new[54]|giv[55]	coref	15-13[0_55]
8-4	1152-1160	polymers	object[54]|substance[55]	new[54]|giv[55]	_	_
8-5	1161-1164	are	_	_	_	_
8-6	1165-1169	also	_	_	_	_
8-7	1170-1179	available	_	_	_	_
8-8	1180-1184	with	_	_	_	_
8-9	1185-1191	better	substance[56]	new[56]	_	_
8-10	1192-1206	hydrophilicity	substance[56]	new[56]	_	_
8-11	1207-1208	,	_	_	_	_
8-12	1209-1213	cell	place|object[58]	giv|new[58]	coref|coref	14-13|14-13
8-13	1214-1224	attachment	object[58]	new[58]	_	_
8-14	1225-1226	,	_	_	_	_
8-15	1227-1230	and	_	_	_	_
8-16	1231-1247	biodegradability	substance	new	coref	12-16
8-17	1248-1249	.	_	_	_	_

#Text=The most used biopolymers are chitosan , alginate ( Alg ) , collagen ( Col ) , gelatin ( Gn ) , silk fibroin ( SF ) , and glycosaminoglycans ( GAGs ) .
9-1	1250-1253	The	substance[60]	new[60]	coref	9-6[61_60]
9-2	1254-1258	most	substance[60]	new[60]	_	_
9-3	1259-1263	used	substance[60]	new[60]	_	_
9-4	1264-1275	biopolymers	substance[60]	new[60]	_	_
9-5	1276-1279	are	_	_	_	_
9-6	1280-1288	chitosan	substance[61]	giv[61]	coref	10-1[0_61]
9-7	1289-1290	,	substance[61]	giv[61]	_	_
9-8	1291-1299	alginate	substance[61]|abstract	giv[61]|new	appos	9-10
9-9	1300-1301	(	substance[61]	giv[61]	_	_
9-10	1302-1305	Alg	substance[61]|abstract	giv[61]|giv	_	_
9-11	1306-1307	)	substance[61]	giv[61]	_	_
9-12	1308-1309	,	substance[61]	giv[61]	_	_
9-13	1310-1318	collagen	substance[61]|organization	giv[61]|new	_	_
9-14	1319-1320	(	substance[61]	giv[61]	_	_
9-15	1321-1324	Col	substance[61]|person	giv[61]|new	_	_
9-16	1325-1326	)	substance[61]	giv[61]	_	_
9-17	1327-1328	,	substance[61]	giv[61]	_	_
9-18	1329-1336	gelatin	substance[61]|substance	giv[61]|new	appos	9-20
9-19	1337-1338	(	substance[61]	giv[61]	_	_
9-20	1339-1341	Gn	substance[61]|substance	giv[61]|giv	_	_
9-21	1342-1343	)	substance[61]	giv[61]	_	_
9-22	1344-1345	,	substance[61]	giv[61]	_	_
9-23	1346-1350	silk	substance[61]|object[68]	giv[61]|new[68]	_	_
9-24	1351-1358	fibroin	substance[61]|object[68]	giv[61]|new[68]	_	_
9-25	1359-1360	(	substance[61]	giv[61]	_	_
9-26	1361-1363	SF	substance[61]|place	giv[61]|new	_	_
9-27	1364-1365	)	substance[61]	giv[61]	_	_
9-28	1366-1367	,	substance[61]	giv[61]	_	_
9-29	1368-1371	and	substance[61]	giv[61]	_	_
9-30	1372-1390	glycosaminoglycans	substance[61]|substance	giv[61]|new	_	_
9-31	1391-1392	(	_	_	_	_
9-32	1393-1397	GAGs	object	new	_	_
9-33	1398-1399	)	_	_	_	_
9-34	1400-1401	.	_	_	_	_

#Text=Chitosan ( CS ) , a natural polymer obtained from the partial deacetylation of chitin , is one of the most common biopolymers on earth .
10-1	1402-1410	Chitosan	substance	giv	appos	10-3
10-2	1411-1412	(	_	_	_	_
10-3	1413-1415	CS	substance	giv	appos	10-6[74_0]
10-4	1416-1417	)	_	_	_	_
10-5	1418-1419	,	_	_	_	_
10-6	1420-1421	a	substance[74]	giv[74]	coref	10-20[78_74]
10-7	1422-1429	natural	substance[74]	giv[74]	_	_
10-8	1430-1437	polymer	substance[74]	giv[74]	_	_
10-9	1438-1446	obtained	_	_	_	_
10-10	1447-1451	from	_	_	_	_
10-11	1452-1455	the	substance[75]	new[75]	_	_
10-12	1456-1463	partial	substance[75]	new[75]	_	_
10-13	1464-1477	deacetylation	substance[75]	new[75]	_	_
10-14	1478-1480	of	substance[75]	new[75]	_	_
10-15	1481-1487	chitin	substance[75]|substance	new[75]|new	_	_
10-16	1488-1489	,	_	_	_	_
10-17	1490-1492	is	_	_	_	_
10-18	1493-1496	one	abstract[77]	new[77]	ana	11-1[0_77]
10-19	1497-1499	of	abstract[77]	new[77]	_	_
10-20	1500-1503	the	abstract[77]|substance[78]	new[77]|giv[78]	coref	12-1[0_78]
10-21	1504-1508	most	abstract[77]|substance[78]	new[77]|giv[78]	_	_
10-22	1509-1515	common	abstract[77]|substance[78]	new[77]|giv[78]	_	_
10-23	1516-1527	biopolymers	abstract[77]|substance[78]	new[77]|giv[78]	_	_
10-24	1528-1530	on	abstract[77]|substance[78]	new[77]|giv[78]	_	_
10-25	1531-1536	earth	abstract[77]|substance[78]|place	new[77]|giv[78]|new	_	_
10-26	1537-1538	.	_	_	_	_

#Text=It is present in the shells of crustaceans such as crab and shrimp .
11-1	1539-1541	It	abstract	giv	_	_
11-2	1542-1544	is	_	_	_	_
11-3	1545-1552	present	_	_	_	_
11-4	1553-1555	in	_	_	_	_
11-5	1556-1559	the	object[81]	new[81]	_	_
11-6	1560-1566	shells	object[81]	new[81]	_	_
11-7	1567-1569	of	object[81]	new[81]	_	_
11-8	1570-1581	crustaceans	object[81]|animal	new[81]|new	_	_
11-9	1582-1586	such	object[81]	new[81]	_	_
11-10	1587-1589	as	object[81]	new[81]	_	_
11-11	1590-1594	crab	object[81]|animal	new[81]|new	_	_
11-12	1595-1598	and	object[81]	new[81]	_	_
11-13	1599-1605	shrimp	object[81]|animal	new[81]|new	_	_
11-14	1606-1607	.	_	_	_	_

#Text=CS has many desirable properties for tissue engineering such as biocompatibility , non-toxicity , and biodegradability .
12-1	1608-1610	CS	abstract	giv	coref	13-1
12-2	1611-1614	has	_	_	_	_
12-3	1615-1619	many	abstract[86]	giv[86]	coref	17-14[148_86]
12-4	1620-1629	desirable	abstract[86]	giv[86]	_	_
12-5	1630-1640	properties	abstract[86]	giv[86]	_	_
12-6	1641-1644	for	abstract[86]	giv[86]	_	_
12-7	1645-1651	tissue	abstract[86]|object|abstract[88]	giv[86]|giv|new[88]	coref|coref|coref|coref	14-6|14-5[119_88]|14-6|14-5[119_88]
12-8	1652-1663	engineering	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-9	1664-1668	such	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-10	1669-1671	as	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-11	1672-1688	biocompatibility	abstract[86]|abstract[88]|abstract	giv[86]|new[88]|new	coref	15-19[131_0]
12-12	1689-1690	,	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-13	1691-1703	non-toxicity	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-14	1704-1705	,	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-15	1706-1709	and	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
12-16	1710-1726	biodegradability	abstract[86]|abstract[88]|substance	giv[86]|new[88]|giv	_	_
12-17	1727-1728	.	_	_	_	_

#Text=CS was used in several tissue-engineering applications involving bone , cartilage , liver , tendons , ligaments and nerves , wound healing , separation membranes , blood anticoagulants , contact lenses , controlled release of drugs , fat-sequestering agent , hydrogel preparations , and food packaging material .
13-1	1729-1731	CS	substance	giv	coref	14-1
13-2	1732-1735	was	_	_	_	_
13-3	1736-1740	used	_	_	_	_
13-4	1741-1743	in	_	_	_	_
13-5	1744-1751	several	abstract[93]	new[93]	coref	19-15[170_93]
13-6	1752-1770	tissue-engineering	abstract|abstract[93]	new|new[93]	_	_
13-7	1771-1783	applications	abstract[93]	new[93]	_	_
13-8	1784-1793	involving	_	_	_	_
13-9	1794-1798	bone	object	new	coref	14-5
13-10	1799-1800	,	_	_	_	_
13-11	1801-1810	cartilage	object	new	_	_
13-12	1811-1812	,	_	_	_	_
13-13	1813-1818	liver	object	new	_	_
13-14	1819-1820	,	_	_	_	_
13-15	1821-1828	tendons	object	new	_	_
13-16	1829-1830	,	_	_	_	_
13-17	1831-1840	ligaments	object	new	_	_
13-18	1841-1844	and	_	_	_	_
13-19	1845-1851	nerves	object	new	_	_
13-20	1852-1853	,	_	_	_	_
13-21	1854-1859	wound	abstract|event[101]	new|new[101]	_	_
13-22	1860-1867	healing	event[101]	new[101]	_	_
13-23	1868-1869	,	_	_	_	_
13-24	1870-1880	separation	abstract|object[103]	new|new[103]	_	_
13-25	1881-1890	membranes	object[103]	new[103]	_	_
13-26	1891-1892	,	_	_	_	_
13-27	1893-1898	blood	substance|substance[105]	new|new[105]	_	_
13-28	1899-1913	anticoagulants	substance[105]	new[105]	_	_
13-29	1914-1915	,	_	_	_	_
13-30	1916-1923	contact	object[106]	new[106]	_	_
13-31	1924-1930	lenses	object[106]	new[106]	_	_
13-32	1931-1932	,	_	_	_	_
13-33	1933-1943	controlled	event[107]	new[107]	_	_
13-34	1944-1951	release	event[107]	new[107]	_	_
13-35	1952-1954	of	event[107]	new[107]	_	_
13-36	1955-1960	drugs	event[107]|substance	new[107]|new	_	_
13-37	1961-1962	,	_	_	_	_
13-38	1963-1979	fat-sequestering	abstract|substance[110]	new|new[110]	_	_
13-39	1980-1985	agent	substance[110]	new[110]	_	_
13-40	1986-1987	,	_	_	_	_
13-41	1988-1996	hydrogel	substance|object[112]	new|new[112]	_	_
13-42	1997-2009	preparations	object[112]	new[112]	_	_
13-43	2010-2011	,	_	_	_	_
13-44	2012-2015	and	_	_	_	_
13-45	2016-2020	food	substance|substance[115]	new|new[115]	_	_
13-46	2021-2030	packaging	abstract|substance[115]	new|new[115]	_	_
13-47	2031-2039	material	substance[115]	new[115]	_	_
13-48	2040-2041	.	_	_	_	_

#Text=CS was evaluated for bone tissue engineering ( BTE ) with good cell adhesion and proliferation observed .
14-1	2042-2044	CS	abstract	giv	coref	15-1
14-2	2045-2048	was	_	_	_	_
14-3	2049-2058	evaluated	_	_	_	_
14-4	2059-2062	for	_	_	_	_
14-5	2063-2067	bone	object|abstract[119]	giv|giv[119]	appos|appos	14-9[0_119]|14-9[0_119]
14-6	2068-2074	tissue	object|abstract[119]	giv|giv[119]	coref	19-17
14-7	2075-2086	engineering	abstract[119]	giv[119]	_	_
14-8	2087-2088	(	_	_	_	_
14-9	2089-2092	BTE	abstract	giv	coref	15-17[130_0]
14-10	2093-2094	)	_	_	_	_
14-11	2095-2099	with	_	_	_	_
14-12	2100-2104	good	abstract[122]	giv[122]	coref	30-34[240_122]
14-13	2105-2109	cell	place|abstract[122]	giv|giv[122]	coref	15-22
14-14	2110-2118	adhesion	abstract[122]	giv[122]	_	_
14-15	2119-2122	and	_	_	_	_
14-16	2123-2136	proliferation	event	giv	coref	15-23
14-17	2137-2145	observed	_	_	_	_
14-18	2146-2147	.	_	_	_	_

#Text=CS composites with different materials such as ceramics , nanofillers , and polymers were evaluated for BTE with excellent biocompatibility and cell proliferation results .
15-1	2148-2150	CS	abstract|object[125]	giv|giv[125]	coref|coref|coref|coref	19-13|26-10[215_125]|19-13|26-10[215_125]
15-2	2151-2161	composites	object[125]	giv[125]	_	_
15-3	2162-2166	with	object[125]	giv[125]	_	_
15-4	2167-2176	different	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-5	2177-2186	materials	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-6	2187-2191	such	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-7	2192-2194	as	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-8	2195-2203	ceramics	object[125]|substance[126]|substance	giv[125]|giv[126]|new	_	_
15-9	2204-2205	,	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-10	2206-2217	nanofillers	object[125]|substance[126]|object	giv[125]|giv[126]|new	coref	20-1[173_0]
15-11	2218-2219	,	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-12	2220-2223	and	object[125]|substance[126]	giv[125]|giv[126]	_	_
15-13	2224-2232	polymers	object[125]|substance[126]|substance	giv[125]|giv[126]|giv	coref	18-9
15-14	2233-2237	were	_	_	_	_
15-15	2238-2247	evaluated	_	_	_	_
15-16	2248-2251	for	_	_	_	_
15-17	2252-2255	BTE	abstract[130]	giv[130]	ana	16-1[0_130]
15-18	2256-2260	with	abstract[130]	giv[130]	_	_
15-19	2261-2270	excellent	abstract[130]|abstract[131]	giv[130]|giv[131]	coref	20-20[176_131]
15-20	2271-2287	biocompatibility	abstract[130]|abstract[131]	giv[130]|giv[131]	_	_
15-21	2288-2291	and	abstract[130]	giv[130]	_	_
15-22	2292-2296	cell	abstract[130]|place|abstract[134]	giv[130]|giv|new[134]	coref|coref|coref|coref	16-16|32-1[259_134]|16-16|32-1[259_134]
15-23	2297-2310	proliferation	abstract[130]|event|abstract[134]	giv[130]|giv|new[134]	coref	30-37
15-24	2311-2318	results	abstract[130]|abstract[134]	giv[130]|new[134]	_	_
15-25	2319-2320	.	_	_	_	_

#Text=It was recognized that amine and hydroxyl groups facilitate the addition of side groups for cell incorporation and recognition in BTE .
16-1	2321-2323	It	abstract	giv	coref	16-21
16-2	2324-2327	was	_	_	_	_
16-3	2328-2338	recognized	_	_	_	_
16-4	2339-2343	that	_	_	_	_
16-5	2344-2349	amine	substance	new	_	_
16-6	2350-2353	and	_	_	_	_
16-7	2354-2362	hydroxyl	organization|person[138]	new|new[138]	coref|coref	16-13[140_138]|16-13[140_138]
16-8	2363-2369	groups	person[138]	new[138]	_	_
16-9	2370-2380	facilitate	_	_	_	_
16-10	2381-2384	the	event[139]	new[139]	_	_
16-11	2385-2393	addition	event[139]	new[139]	_	_
16-12	2394-2396	of	event[139]	new[139]	_	_
16-13	2397-2401	side	event[139]|person[140]	new[139]|giv[140]	coref	22-15[197_140]
16-14	2402-2408	groups	event[139]|person[140]	new[139]|giv[140]	_	_
16-15	2409-2412	for	event[139]|person[140]	new[139]|giv[140]	_	_
16-16	2413-2417	cell	event[139]|person[140]|place|event[142]	new[139]|giv[140]|giv|new[142]	coref|coref	24-9|24-9
16-17	2418-2431	incorporation	event[139]|person[140]|event[142]	new[139]|giv[140]|new[142]	_	_
16-18	2432-2435	and	event[139]|person[140]	new[139]|giv[140]	_	_
16-19	2436-2447	recognition	event[139]|person[140]|abstract[143]	new[139]|giv[140]|new[143]	ana	17-8[0_143]
16-20	2448-2450	in	event[139]|person[140]|abstract[143]	new[139]|giv[140]|new[143]	_	_
16-21	2451-2454	BTE	event[139]|person[140]|abstract[143]|substance	new[139]|giv[140]|new[143]|giv	coref	19-17[172_0]
16-22	2455-2456	.	_	_	_	_

#Text=However , like many other polysaccharides , it presents some disadvantages such as poor mechanical properties , poor solubility in conventional solvents , and poor stability in physiological media due to the high amount of hydrogen bonding .
17-1	2457-2464	However	_	_	_	_
17-2	2465-2466	,	_	_	_	_
17-3	2467-2471	like	_	_	_	_
17-4	2472-2476	many	substance[145]	new[145]	_	_
17-5	2477-2482	other	substance[145]	new[145]	_	_
17-6	2483-2498	polysaccharides	substance[145]	new[145]	_	_
17-7	2499-2500	,	_	_	_	_
17-8	2501-2503	it	abstract	giv	coref	30-41[243_0]
17-9	2504-2512	presents	_	_	_	_
17-10	2513-2517	some	abstract[147]	new[147]	coref	18-16[161_147]
17-11	2518-2531	disadvantages	abstract[147]	new[147]	_	_
17-12	2532-2536	such	abstract[147]	new[147]	_	_
17-13	2537-2539	as	abstract[147]	new[147]	_	_
17-14	2540-2544	poor	abstract[147]|abstract[148]	new[147]|giv[148]	coref	27-1[217_148]
17-15	2545-2555	mechanical	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
17-16	2556-2566	properties	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
17-17	2567-2568	,	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
17-18	2569-2573	poor	abstract[147]|abstract[148]|substance[149]	new[147]|giv[148]|new[149]	_	_
17-19	2574-2584	solubility	abstract[147]|abstract[148]|substance[149]	new[147]|giv[148]|new[149]	_	_
17-20	2585-2587	in	abstract[147]|abstract[148]|substance[149]	new[147]|giv[148]|new[149]	_	_
17-21	2588-2600	conventional	abstract[147]|abstract[148]|substance[149]|substance[150]	new[147]|giv[148]|new[149]|new[150]	_	_
17-22	2601-2609	solvents	abstract[147]|abstract[148]|substance[149]|substance[150]	new[147]|giv[148]|new[149]|new[150]	_	_
17-23	2610-2611	,	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
17-24	2612-2615	and	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
17-25	2616-2620	poor	abstract[147]|abstract[148]|abstract[151]	new[147]|giv[148]|new[151]	coref	20-13[175_151]
17-26	2621-2630	stability	abstract[147]|abstract[148]|abstract[151]	new[147]|giv[148]|new[151]	_	_
17-27	2631-2633	in	abstract[147]|abstract[148]|abstract[151]	new[147]|giv[148]|new[151]	_	_
17-28	2634-2647	physiological	abstract[147]|abstract[148]|abstract[151]|abstract[152]	new[147]|giv[148]|new[151]|new[152]	_	_
17-29	2648-2653	media	abstract[147]|abstract[148]|abstract[151]|abstract[152]	new[147]|giv[148]|new[151]|new[152]	_	_
17-30	2654-2657	due	abstract[147]|abstract[148]|abstract[151]|abstract[152]	new[147]|giv[148]|new[151]|new[152]	_	_
17-31	2658-2660	to	_	_	_	_
17-32	2661-2664	the	abstract[153]	new[153]	_	_
17-33	2665-2669	high	abstract[153]	new[153]	_	_
17-34	2670-2676	amount	abstract[153]	new[153]	_	_
17-35	2677-2679	of	abstract[153]	new[153]	_	_
17-36	2680-2688	hydrogen	abstract[153]|substance|abstract[155]	new[153]|new|new[155]	_	_
17-37	2689-2696	bonding	abstract[153]|abstract[155]	new[153]|new[155]	_	_
17-38	2697-2698	.	_	_	_	_

#Text=Many studies addressed the physicochemical attributes of nanocomposite polymers thanks to their effectiveness in overcoming the disadvantages of naturally occurring polymers .
18-1	2699-2703	Many	event[156]	new[156]	coref	30-13[235_156]
18-2	2704-2711	studies	event[156]	new[156]	_	_
18-3	2712-2721	addressed	_	_	_	_
18-4	2722-2725	the	abstract[157]	new[157]	_	_
18-5	2726-2741	physicochemical	abstract[157]	new[157]	_	_
18-6	2742-2752	attributes	abstract[157]	new[157]	_	_
18-7	2753-2755	of	abstract[157]	new[157]	_	_
18-8	2756-2769	nanocomposite	abstract[157]|person	new[157]|new	coref	31-20
18-9	2770-2778	polymers	abstract[157]|substance	new[157]|giv	coref	18-21
18-10	2779-2785	thanks	abstract[157]	new[157]	_	_
18-11	2786-2788	to	abstract[157]	new[157]	_	_
18-12	2789-2794	their	abstract[157]|abstract[160]	new[157]|new[160]	_	_
18-13	2795-2808	effectiveness	abstract[157]|abstract[160]	new[157]|new[160]	_	_
18-14	2809-2811	in	_	_	_	_
18-15	2812-2822	overcoming	_	_	_	_
18-16	2823-2826	the	abstract[161]	giv[161]	_	_
18-17	2827-2840	disadvantages	abstract[161]	giv[161]	_	_
18-18	2841-2843	of	_	_	_	_
18-19	2844-2853	naturally	_	_	_	_
18-20	2854-2863	occurring	_	_	_	_
18-21	2864-2872	polymers	substance	giv	_	_
18-22	2873-2874	.	_	_	_	_

#Text=Our group investigated the use of nanocomposites based on graphene oxide and chitosan for applications in tissue engineering .
19-1	2875-2878	Our	person|organization[164]	acc|new[164]	_	_
19-2	2879-2884	group	organization[164]	new[164]	_	_
19-3	2885-2897	investigated	_	_	_	_
19-4	2898-2901	the	abstract[165]	new[165]	_	_
19-5	2902-2905	use	abstract[165]	new[165]	_	_
19-6	2906-2908	of	abstract[165]	new[165]	_	_
19-7	2909-2923	nanocomposites	abstract[165]|object	new[165]|new	coref	20-23[177_0]
19-8	2924-2929	based	_	_	_	_
19-9	2930-2932	on	_	_	_	_
19-10	2933-2941	graphene	abstract|substance[168]	new|new[168]	_	_
19-11	2942-2947	oxide	substance[168]	new[168]	_	_
19-12	2948-2951	and	_	_	_	_
19-13	2952-2960	chitosan	substance	giv	coref	20-25
19-14	2961-2964	for	_	_	_	_
19-15	2965-2977	applications	abstract[170]	giv[170]	coref	23-5[201_170]
19-16	2978-2980	in	abstract[170]	giv[170]	_	_
19-17	2981-2987	tissue	abstract[170]|object|abstract[172]	giv[170]|giv|giv[172]	coref|coref|coref|coref	32-23|32-23[266_172]|32-23|32-23[266_172]
19-18	2988-2999	engineering	abstract[170]|abstract[172]	giv[170]|giv[172]	_	_
19-19	3000-3001	.	_	_	_	_

#Text=Even with the nanofillers , there is still a need to achieve better mechanical and thermal stability combined with higher biocompatibility in nanocomposites of chitosan and carbon nanomaterials .
20-1	3002-3006	Even	object[173]	giv[173]	_	_
20-2	3007-3011	with	object[173]	giv[173]	_	_
20-3	3012-3015	the	object[173]	giv[173]	_	_
20-4	3016-3027	nanofillers	object[173]	giv[173]	_	_
20-5	3028-3029	,	_	_	_	_
20-6	3030-3035	there	_	_	_	_
20-7	3036-3038	is	_	_	_	_
20-8	3039-3044	still	_	_	_	_
20-9	3045-3046	a	abstract[174]	new[174]	_	_
20-10	3047-3051	need	abstract[174]	new[174]	_	_
20-11	3052-3054	to	_	_	_	_
20-12	3055-3062	achieve	_	_	_	_
20-13	3063-3069	better	abstract[175]	giv[175]	_	_
20-14	3070-3080	mechanical	abstract[175]	giv[175]	_	_
20-15	3081-3084	and	abstract[175]	giv[175]	_	_
20-16	3085-3092	thermal	abstract[175]	giv[175]	_	_
20-17	3093-3102	stability	abstract[175]	giv[175]	_	_
20-18	3103-3111	combined	_	_	_	_
20-19	3112-3116	with	_	_	_	_
20-20	3117-3123	higher	abstract[176]	giv[176]	coref	33-14[0_176]
20-21	3124-3140	biocompatibility	abstract[176]	giv[176]	_	_
20-22	3141-3143	in	abstract[176]	giv[176]	_	_
20-23	3144-3158	nanocomposites	abstract[176]|object[177]	giv[176]|giv[177]	_	_
20-24	3159-3161	of	abstract[176]|object[177]	giv[176]|giv[177]	_	_
20-25	3162-3170	chitosan	abstract[176]|object[177]|substance	giv[176]|giv[177]|giv	coref	26-8
20-26	3171-3174	and	abstract[176]|object[177]	giv[176]|giv[177]	_	_
20-27	3175-3181	carbon	abstract[176]|object[177]|object[179]	giv[176]|giv[177]|new[179]	_	_
20-28	3182-3195	nanomaterials	abstract[176]|object[177]|object[179]	giv[176]|giv[177]|new[179]	_	_
20-29	3196-3197	.	_	_	_	_

#Text=Carbon nano-onions ( CNOs ) are multi-shell fullerenes of 5 to 10 nm , discovered by Ugarte in 1992 upon impacting carbon nanostructures with an electron beam through a TEM experiment .
21-1	3198-3204	Carbon	person|object[181]	new|new[181]	appos|appos	21-4[0_181]|21-4[0_181]
21-2	3205-3216	nano-onions	object[181]	new[181]	_	_
21-3	3217-3218	(	_	_	_	_
21-4	3219-3223	CNOs	object	giv	coref	21-7[183_0]
21-5	3224-3225	)	_	_	_	_
21-6	3226-3229	are	_	_	_	_
21-7	3230-3241	multi-shell	object[183]	giv[183]	coref	22-6[0_183]
21-8	3242-3252	fullerenes	object[183]	giv[183]	_	_
21-9	3253-3255	of	object[183]	giv[183]	_	_
21-10	3256-3257	5	object[183]|quantity	giv[183]|new	_	_
21-11	3258-3260	to	object[183]	giv[183]	_	_
21-12	3261-3263	10	object[183]|quantity[185]	giv[183]|new[185]	_	_
21-13	3264-3266	nm	object[183]|quantity[185]	giv[183]|new[185]	_	_
21-14	3267-3268	,	_	_	_	_
21-15	3269-3279	discovered	_	_	_	_
21-16	3280-3282	by	_	_	_	_
21-17	3283-3289	Ugarte	person	new	_	_
21-18	3290-3292	in	_	_	_	_
21-19	3293-3297	1992	time	new	_	_
21-20	3298-3302	upon	_	_	_	_
21-21	3303-3312	impacting	_	_	_	_
21-22	3313-3319	carbon	substance|object[189]	new|new[189]	_	_
21-23	3320-3334	nanostructures	object[189]	new[189]	_	_
21-24	3335-3339	with	_	_	_	_
21-25	3340-3342	an	object[191]	new[191]	_	_
21-26	3343-3351	electron	substance|object[191]	new|new[191]	_	_
21-27	3352-3356	beam	object[191]	new[191]	_	_
21-28	3357-3364	through	object[191]	new[191]	_	_
21-29	3365-3366	a	object[191]|object[193]	new[191]|new[193]	_	_
21-30	3367-3370	TEM	object[191]|place|object[193]	new[191]|new|new[193]	_	_
21-31	3371-3381	experiment	object[191]|object[193]	new[191]|new[193]	_	_
21-32	3382-3383	.	_	_	_	_

#Text=For the chemical derivatization of CNOs , various synthetic routes were applied , introducing new functional groups that increase their application possibilities .
22-1	3384-3387	For	_	_	_	_
22-2	3388-3391	the	abstract[194]	new[194]	_	_
22-3	3392-3400	chemical	abstract[194]	new[194]	_	_
22-4	3401-3415	derivatization	abstract[194]	new[194]	_	_
22-5	3416-3418	of	abstract[194]	new[194]	_	_
22-6	3419-3423	CNOs	abstract[194]|substance	new[194]|giv	coref	24-1
22-7	3424-3425	,	_	_	_	_
22-8	3426-3433	various	abstract[196]	new[196]	_	_
22-9	3434-3443	synthetic	abstract[196]	new[196]	_	_
22-10	3444-3450	routes	abstract[196]	new[196]	_	_
22-11	3451-3455	were	_	_	_	_
22-12	3456-3463	applied	_	_	_	_
22-13	3464-3465	,	_	_	_	_
22-14	3466-3477	introducing	_	_	_	_
22-15	3478-3481	new	person[197]	giv[197]	ana	22-20[0_197]
22-16	3482-3492	functional	person[197]	giv[197]	_	_
22-17	3493-3499	groups	person[197]	giv[197]	_	_
22-18	3500-3504	that	_	_	_	_
22-19	3505-3513	increase	_	_	_	_
22-20	3514-3519	their	person|abstract[200]	giv|new[200]	_	_
22-21	3520-3531	application	abstract|abstract[200]	new|new[200]	coref	32-19[264_0]
22-22	3532-3545	possibilities	abstract[200]	new[200]	_	_
22-23	3546-3547	.	_	_	_	_

#Text=Some potential uses include optical applications , catalysis , and gas storage .
23-1	3548-3552	Some	_	_	_	_
23-2	3553-3562	potential	_	_	_	_
23-3	3563-3567	uses	_	_	_	_
23-4	3568-3575	include	_	_	_	_
23-5	3576-3583	optical	abstract[201]	giv[201]	coref	24-6[207_201]
23-6	3584-3596	applications	abstract[201]	giv[201]	_	_
23-7	3597-3598	,	abstract[201]	giv[201]	_	_
23-8	3599-3608	catalysis	abstract[201]|substance	giv[201]|new	_	_
23-9	3609-3610	,	abstract[201]	giv[201]	_	_
23-10	3611-3614	and	abstract[201]	giv[201]	_	_
23-11	3615-3618	gas	abstract[201]|substance|abstract[204]	giv[201]|new|new[204]	_	_
23-12	3619-3626	storage	abstract[201]|abstract[204]	giv[201]|new[204]	_	_
23-13	3627-3628	.	_	_	_	_

#Text=CNOs are also useful in photovoltaic and fuel cell applications .
24-1	3629-3633	CNOs	object	giv	coref	27-8
24-2	3634-3637	are	_	_	_	_
24-3	3638-3642	also	_	_	_	_
24-4	3643-3649	useful	_	_	_	_
24-5	3650-3652	in	_	_	_	_
24-6	3653-3665	photovoltaic	abstract[207]	giv[207]	ana	25-1[0_207]
24-7	3666-3669	and	abstract[207]	giv[207]	_	_
24-8	3670-3674	fuel	abstract[207]	giv[207]	_	_
24-9	3675-3679	cell	object|abstract[207]	giv|giv[207]	coref	30-34
24-10	3680-3692	applications	abstract[207]	giv[207]	_	_
24-11	3693-3694	.	_	_	_	_

#Text=They demonstrated a superior lubrication ability compared to conventional lubricants .
25-1	3695-3699	They	abstract	giv	coref	28-14[228_0]
25-2	3700-3712	demonstrated	_	_	_	_
25-3	3713-3714	a	abstract[210]	new[210]	_	_
25-4	3715-3723	superior	abstract[210]	new[210]	_	_
25-5	3724-3735	lubrication	substance|abstract[210]	new|new[210]	_	_
25-6	3736-3743	ability	abstract[210]	new[210]	_	_
25-7	3744-3752	compared	_	_	_	_
25-8	3753-3755	to	_	_	_	_
25-9	3756-3768	conventional	abstract[211]	new[211]	_	_
25-10	3769-3779	lubricants	abstract[211]	new[211]	_	_
25-11	3780-3781	.	_	_	_	_

#Text=However , there are few reports of CS and CNO composites in the literature .
26-1	3782-3789	However	_	_	_	_
26-2	3790-3791	,	_	_	_	_
26-3	3792-3797	there	_	_	_	_
26-4	3798-3801	are	_	_	_	_
26-5	3802-3805	few	abstract[212]	new[212]	_	_
26-6	3806-3813	reports	abstract[212]	new[212]	_	_
26-7	3814-3816	of	abstract[212]	new[212]	_	_
26-8	3817-3819	CS	abstract[212]|abstract	new[212]|giv	coref	27-18
26-9	3820-3823	and	abstract[212]	new[212]	_	_
26-10	3824-3827	CNO	abstract[212]|abstract|object[215]	new[212]|new|giv[215]	coref|coref	27-5[0_215]|27-5[0_215]
26-11	3828-3838	composites	abstract[212]|object[215]	new[212]|giv[215]	_	_
26-12	3839-3841	in	abstract[212]|object[215]	new[212]|giv[215]	_	_
26-13	3842-3845	the	abstract[212]|object[215]|abstract[216]	new[212]|giv[215]|new[216]	coref	28-4[0_216]
26-14	3846-3856	literature	abstract[212]|object[215]|abstract[216]	new[212]|giv[215]|new[216]	_	_
26-15	3857-3858	.	_	_	_	_

#Text=The electrochemical properties of composites consisting of CNOs and poly(diallyl dimethylammonium chloride ) ( PDDA ) or chitosan ( CS ) were reported .
27-1	3859-3862	The	abstract[217]	giv[217]	_	_
27-2	3863-3878	electrochemical	abstract[217]	giv[217]	_	_
27-3	3879-3889	properties	abstract[217]	giv[217]	_	_
27-4	3890-3892	of	abstract[217]	giv[217]	_	_
27-5	3893-3903	composites	abstract[217]|object	giv[217]|giv	_	_
27-6	3904-3914	consisting	_	_	_	_
27-7	3915-3917	of	_	_	_	_
27-8	3918-3922	CNOs	substance	giv	appos	27-10[220_0]
27-9	3923-3926	and	_	_	_	_
27-10	3927-3939	poly(diallyl	substance[220]	giv[220]	coref	29-12[0_220]
27-11	3940-3956	dimethylammonium	substance[220]	giv[220]	_	_
27-12	3957-3965	chloride	substance[220]	giv[220]	_	_
27-13	3966-3967	)	_	_	_	_
27-14	3968-3969	(	_	_	_	_
27-15	3970-3974	PDDA	_	_	_	_
27-16	3975-3976	)	_	_	_	_
27-17	3977-3979	or	_	_	_	_
27-18	3980-3988	chitosan	substance	giv	coref	27-20
27-19	3989-3990	(	_	_	_	_
27-20	3991-3993	CS	abstract	giv	coref	28-8
27-21	3994-3995	)	_	_	_	_
27-22	3996-4000	were	_	_	_	_
27-23	4001-4009	reported	_	_	_	_
27-24	4010-4011	.	_	_	_	_

#Text=The lack of literature regarding nanocomposites of CS and oxidized ( ox-)CNOs for biomedical applications is evident .
28-1	4012-4015	The	abstract[223]	new[223]	_	_
28-2	4016-4020	lack	abstract[223]	new[223]	_	_
28-3	4021-4023	of	abstract[223]	new[223]	_	_
28-4	4024-4034	literature	abstract[223]|abstract	new[223]|giv	_	_
28-5	4035-4044	regarding	_	_	_	_
28-6	4045-4059	nanocomposites	substance[225]	new[225]	coref	32-12[262_225]
28-7	4060-4062	of	substance[225]	new[225]	_	_
28-8	4063-4065	CS	substance[225]|substance	new[225]|giv	_	_
28-9	4066-4069	and	substance[225]	new[225]	_	_
28-10	4070-4078	oxidized	substance[225]	new[225]	_	_
28-11	4079-4080	(	_	_	_	_
28-12	4081-4089	ox-)CNOs	abstract[227]	new[227]	_	_
28-13	4090-4093	for	abstract[227]	new[227]	_	_
28-14	4094-4104	biomedical	abstract[227]|abstract[228]	new[227]|giv[228]	ana	30-1[0_228]
28-15	4105-4117	applications	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
28-16	4118-4120	is	_	_	_	_
28-17	4121-4128	evident	_	_	_	_
28-18	4129-4130	.	_	_	_	_

#Text=Very few studies were carried out to determine the cytotoxicity of CNOs .
29-1	4131-4135	Very	event[229]	new[229]	_	_
29-2	4136-4139	few	event[229]	new[229]	_	_
29-3	4140-4147	studies	event[229]	new[229]	_	_
29-4	4148-4152	were	_	_	_	_
29-5	4153-4160	carried	_	_	_	_
29-6	4161-4164	out	_	_	_	_
29-7	4165-4167	to	_	_	_	_
29-8	4168-4177	determine	_	_	_	_
29-9	4178-4181	the	abstract[230]	new[230]	_	_
29-10	4182-4194	cytotoxicity	abstract[230]	new[230]	_	_
29-11	4195-4197	of	abstract[230]	new[230]	_	_
29-12	4198-4202	CNOs	abstract[230]|abstract	new[230]|giv	_	_
29-13	4203-4204	.	_	_	_	_

#Text=They were even used for the treatment of cancer ; however , many more studies are still required to show whether they are toxic or if , on the contrary , they promote cell adhesion and proliferation , while facilitating the recognition and permanence of scaffolds in animal tissues without immune responses .
30-1	4205-4209	They	abstract	giv	ana	30-22
30-2	4210-4214	were	_	_	_	_
30-3	4215-4219	even	_	_	_	_
30-4	4220-4224	used	_	_	_	_
30-5	4225-4228	for	_	_	_	_
30-6	4229-4232	the	event[233]	new[233]	_	_
30-7	4233-4242	treatment	event[233]	new[233]	_	_
30-8	4243-4245	of	event[233]	new[233]	_	_
30-9	4246-4252	cancer	event[233]|abstract	new[233]|new	_	_
30-10	4253-4254	;	_	_	_	_
30-11	4255-4262	however	_	_	_	_
30-12	4263-4264	,	_	_	_	_
30-13	4265-4269	many	event[235]	giv[235]	coref	33-14[272_235]
30-14	4270-4274	more	event[235]	giv[235]	_	_
30-15	4275-4282	studies	event[235]	giv[235]	_	_
30-16	4283-4286	are	_	_	_	_
30-17	4287-4292	still	_	_	_	_
30-18	4293-4301	required	_	_	_	_
30-19	4302-4304	to	_	_	_	_
30-20	4305-4309	show	_	_	_	_
30-21	4310-4317	whether	_	_	_	_
30-22	4318-4322	they	abstract	giv	ana	30-32
30-23	4323-4326	are	_	_	_	_
30-24	4327-4332	toxic	_	_	_	_
30-25	4333-4335	or	_	_	_	_
30-26	4336-4338	if	_	_	_	_
30-27	4339-4340	,	_	_	_	_
30-28	4341-4343	on	_	_	_	_
30-29	4344-4347	the	abstract[237]	new[237]	_	_
30-30	4348-4356	contrary	abstract[237]	new[237]	_	_
30-31	4357-4358	,	_	_	_	_
30-32	4359-4363	they	abstract	giv	_	_
30-33	4364-4371	promote	_	_	_	_
30-34	4372-4376	cell	place|abstract[240]|abstract[241]	giv|giv[240]|giv[241]	_	_
30-35	4377-4385	adhesion	abstract[240]|abstract[241]	giv[240]|giv[241]	_	_
30-36	4386-4389	and	abstract[241]	giv[241]	_	_
30-37	4390-4403	proliferation	abstract[241]|event	giv[241]|giv	_	_
30-38	4404-4405	,	_	_	_	_
30-39	4406-4411	while	_	_	_	_
30-40	4412-4424	facilitating	_	_	_	_
30-41	4425-4428	the	abstract[243]	giv[243]	_	_
30-42	4429-4440	recognition	abstract[243]	giv[243]	_	_
30-43	4441-4444	and	_	_	_	_
30-44	4445-4455	permanence	abstract[244]	new[244]	_	_
30-45	4456-4458	of	abstract[244]	new[244]	_	_
30-46	4459-4468	scaffolds	abstract[244]|object[245]	new[244]|new[245]	_	_
30-47	4469-4471	in	abstract[244]|object[245]	new[244]|new[245]	_	_
30-48	4472-4478	animal	abstract[244]|object[245]|animal|place[247]	new[244]|new[245]|new|new[247]	_	_
30-49	4479-4486	tissues	abstract[244]|object[245]|place[247]	new[244]|new[245]|new[247]	_	_
30-50	4487-4494	without	abstract[244]|object[245]	new[244]|new[245]	_	_
30-51	4495-4501	immune	abstract[244]|object[245]|abstract[248]	new[244]|new[245]|new[248]	ana	31-8[0_248]
30-52	4502-4511	responses	abstract[244]|object[245]|abstract[248]	new[244]|new[245]|new[248]	_	_
30-53	4512-4513	.	_	_	_	_

#Text=There is a lack of information on their characterization including the physical , chemical , and mechanical evaluation of nanocomposite films based on CS/poly(vinyl alcohol ) ( PVA)/ox-CNO , together with biological tests in vitro and in vivo .
31-1	4514-4519	There	_	_	_	_
31-2	4520-4522	is	_	_	_	_
31-3	4523-4524	a	abstract[249]	new[249]	_	_
31-4	4525-4529	lack	abstract[249]	new[249]	_	_
31-5	4530-4532	of	abstract[249]	new[249]	_	_
31-6	4533-4544	information	abstract[249]|abstract	new[249]|new	coref	32-9[261_0]
31-7	4545-4547	on	abstract[249]	new[249]	_	_
31-8	4548-4553	their	abstract[249]|abstract|abstract[252]	new[249]|giv|new[252]	_	_
31-9	4554-4570	characterization	abstract[249]|abstract[252]	new[249]|new[252]	_	_
31-10	4571-4580	including	abstract[249]|abstract[252]	new[249]|new[252]	_	_
31-11	4581-4584	the	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-12	4585-4593	physical	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-13	4594-4595	,	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-14	4596-4604	chemical	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-15	4605-4606	,	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-16	4607-4610	and	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-17	4611-4621	mechanical	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-18	4622-4632	evaluation	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-19	4633-4635	of	abstract[249]|abstract[252]|abstract[253]	new[249]|new[252]|new[253]	_	_
31-20	4636-4649	nanocomposite	abstract[249]|abstract[252]|abstract[253]|person|object[255]	new[249]|new[252]|new[253]|giv|new[255]	coref|coref	33-6[268_255]|33-6[268_255]
31-21	4650-4655	films	abstract[249]|abstract[252]|abstract[253]|object[255]	new[249]|new[252]|new[253]|new[255]	_	_
31-22	4656-4661	based	_	_	_	_
31-23	4662-4664	on	_	_	_	_
31-24	4665-4678	CS/poly(vinyl	substance|substance[257]	new|new[257]	_	_
31-25	4679-4686	alcohol	substance[257]	new[257]	_	_
31-26	4687-4688	)	_	_	_	_
31-27	4689-4690	(	_	_	_	_
31-28	4691-4702	PVA)/ox-CNO	_	_	_	_
31-29	4703-4704	,	_	_	_	_
31-30	4705-4713	together	_	_	_	_
31-31	4714-4718	with	_	_	_	_
31-32	4719-4729	biological	abstract[258]	new[258]	_	_
31-33	4730-4735	tests	abstract[258]	new[258]	_	_
31-34	4736-4738	in	abstract[258]	new[258]	_	_
31-35	4739-4744	vitro	abstract[258]	new[258]	_	_
31-36	4745-4748	and	_	_	_	_
31-37	4749-4751	in	_	_	_	_
31-38	4752-4756	vivo	_	_	_	_
31-39	4757-4758	.	_	_	_	_

#Text=The results of this investigation will allow collecting toxicological information for these nanocomposites , as well as evaluating their possible application in tissue engineering .
32-1	4759-4762	The	abstract[259]	giv[259]	_	_
32-2	4763-4770	results	abstract[259]	giv[259]	_	_
32-3	4771-4773	of	abstract[259]	giv[259]	_	_
32-4	4774-4778	this	abstract[259]|abstract[260]	giv[259]|new[260]	_	_
32-5	4779-4792	investigation	abstract[259]|abstract[260]	giv[259]|new[260]	_	_
32-6	4793-4797	will	_	_	_	_
32-7	4798-4803	allow	_	_	_	_
32-8	4804-4814	collecting	_	_	_	_
32-9	4815-4828	toxicological	abstract[261]	giv[261]	_	_
32-10	4829-4840	information	abstract[261]	giv[261]	_	_
32-11	4841-4844	for	abstract[261]	giv[261]	_	_
32-12	4845-4850	these	abstract[261]|object[262]	giv[261]|giv[262]	ana	32-19[0_262]
32-13	4851-4865	nanocomposites	abstract[261]|object[262]	giv[261]|giv[262]	_	_
32-14	4866-4867	,	_	_	_	_
32-15	4868-4870	as	_	_	_	_
32-16	4871-4875	well	_	_	_	_
32-17	4876-4878	as	_	_	_	_
32-18	4879-4889	evaluating	_	_	_	_
32-19	4890-4895	their	object|abstract[264]	giv|giv[264]	_	_
32-20	4896-4904	possible	abstract[264]	giv[264]	_	_
32-21	4905-4916	application	abstract[264]	giv[264]	_	_
32-22	4917-4919	in	abstract[264]	giv[264]	_	_
32-23	4920-4926	tissue	abstract[264]|object|abstract[266]	giv[264]|giv|giv[266]	_	_
32-24	4927-4938	engineering	abstract[264]|abstract[266]	giv[264]|giv[266]	_	_
32-25	4939-4940	.	_	_	_	_

#Text=Therefore , this research investigates nanocomposite films of PVA/CS reinforced with ox-CNOs for biocompatibility studies at 90 days of subdermal implantation in biomodel skin .
33-1	4941-4950	Therefore	_	_	_	_
33-2	4951-4952	,	_	_	_	_
33-3	4953-4957	this	abstract[267]	new[267]	_	_
33-4	4958-4966	research	abstract[267]	new[267]	_	_
33-5	4967-4979	investigates	_	_	_	_
33-6	4980-4993	nanocomposite	object[268]	giv[268]	_	_
33-7	4994-4999	films	object[268]	giv[268]	_	_
33-8	5000-5002	of	object[268]	giv[268]	_	_
33-9	5003-5009	PVA/CS	object[268]|substance	giv[268]|new	_	_
33-10	5010-5020	reinforced	_	_	_	_
33-11	5021-5025	with	_	_	_	_
33-12	5026-5033	ox-CNOs	object	new	_	_
33-13	5034-5037	for	_	_	_	_
33-14	5038-5054	biocompatibility	abstract|event[272]	giv|giv[272]	_	_
33-15	5055-5062	studies	event[272]	giv[272]	_	_
33-16	5063-5065	at	event[272]	giv[272]	_	_
33-17	5066-5068	90	event[272]|time[273]	giv[272]|new[273]	_	_
33-18	5069-5073	days	event[272]|time[273]	giv[272]|new[273]	_	_
33-19	5074-5076	of	event[272]|time[273]	giv[272]|new[273]	_	_
33-20	5077-5086	subdermal	event[272]|time[273]|object[274]	giv[272]|new[273]|new[274]	_	_
33-21	5087-5099	implantation	event[272]|time[273]|object[274]	giv[272]|new[273]|new[274]	_	_
33-22	5100-5102	in	event[272]|time[273]|object[274]	giv[272]|new[273]|new[274]	_	_
33-23	5103-5111	biomodel	event[272]|time[273]|object[274]|object[275]	giv[272]|new[273]|new[274]|new[275]	_	_
33-24	5112-5116	skin	event[272]|time[273]|object[274]|object[275]	giv[272]|new[273]|new[274]|new[275]	_	_
33-25	5117-5118	.	_	_	_	_
